SSG
CBST

Summit Securities Group’s CUBIST PHARMACEUTICALS INC CBST Stock Holding History

Summit Securities Group’s Portfolio CBST Stock Details CBST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,071
Closed -$52K – 676
2013
Q2 		$52K Buy
+1,071
New +$52.6K 0.02% 184

Other funds holding CBST

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Summit Securities Group's CBST Position: Q3 2013 in Review

Summit Securities Group sold out of CUBIST PHARMACEUTICALS INC (CBST) in Q3 2013, closing a stake of 1,071 shares — an estimated $52K sold.

Summit Securities Group first reported a position in CBST in Q2 2013 and held it in 1 quarter. The position peaked at $52K in Q2 2013. 271 funds tracked by Wall St. Rank hold CBST as of Q3 2013.

  • Summit Securities Group reported no remaining CUBIST PHARMACEUTICALS INC position as of Q3 2013 after selling out during the quarter.
  • Summit Securities Group sold 1,071 CUBIST PHARMACEUTICALS INC shares in Q3 2013, an estimated $52K.
  • Summit Securities Group first reported a position in CUBIST PHARMACEUTICALS INC in Q2 2013 and held it in 1 quarter.
  • Summit Securities Group's CUBIST PHARMACEUTICALS INC position peaked at $52K in Q2 2013.
  • 271 funds tracked by Wall St. Rank held CUBIST PHARMACEUTICALS INC as of Q3 2013.

Based on Summit Securities Group's 13F filing for Q3 2013, filed 1 Nov 2013.